Incretin-based investigational therapies for the treatment of MASLD/MASH

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is the most common form of chronic liver disease. It exists as either simple steatosis or its more progressive form, metabolic dysfunction-associated steatohepatitis (MASH), formerly, non-alcoholic steatohepatitis (NASH). The global prevalence of MASLD is estimated to be 32% among adults and is projected to continue to rise with increasing rates of obesity, type 2 diabetes, and metabolic syndrome.

Source: Diabetes Research and Clinical Practice - April 16, 2024 Category: Endocrinology Authors: Bram Brouwers, Girish Rao, Yuanyuan Tang, Ángel Rodríguez, Leonard C Glass, Mark L Hartman Source Type: research